Personalized GVHD Mitigation Systems
Legal Citation
Summary of the Inventive Concept
A next-generation system for mitigating graft versus host disease (GVHD) after hematopoietic cell transplantation (HCT) by leveraging AI-driven dosing regimens, genomic profiling, and real-time monitoring to provide personalized treatment and reduce the risk of GVHD.
Background and Problem Solved
The original patent disclosed methods for reducing the risk of GVHD after HCT by administering alpha-1 antitrypsin (A1AT) according to specific schedules. However, these methods have limitations, including the lack of personalized dosing and real-time monitoring. The new inventive concept addresses these limitations by introducing AI-driven dosing regimens, genomic profiling, and real-time monitoring to provide more effective and targeted treatment.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for mitigating GVHD, which includes a personalized, AI-driven dosing regimen of A1AT tailored to an individual patient's genomic profile. The dosing regimen is adjusted in real-time based on machine learning algorithms analyzing the patient's response to treatment. Additionally, the system includes a deep learning model for predicting the likelihood of GVHD onset, a nanosensor-based device for in vivo monitoring of A1AT levels, a method for generating personalized, 3D-printed implants, and a system for remote monitoring and management of GVHD.
Novelty and Inventive Step
The new claims introduce the use of AI-driven dosing regimens, genomic profiling, and real-time monitoring, which are not present in the original patent. The combination of these elements provides a novel and non-obvious approach to mitigating GVHD.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, genomic profiling techniques, or monitoring devices. Additionally, the system could be adapted for use in other types of transplantation or for treating other diseases.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the field of hematopoietic cell transplantation, particularly in the treatment of GVHD. The system could be marketed to hospitals, research institutions, and pharmaceutical companies, with potential applications in personalized medicine, regenerative medicine, and remote patient monitoring.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/57 |
| A | A61 | A61K35/12 |
| A | A61 | A61P37/06 |
| A | A61 | A61K2035/124 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology focused on hematopoietic cell transplantation (HCT), immunotherapy, and personalized medicine, with expertise in immunosuppressive treatments, protein therapeutics, and advanced monitoring technologies
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinician with advanced degrees in biomedical engineering, immunology, or medical technology, possessing expertise in transplantation medicine, AI-driven medical technologies, and personalized treatment strategies
Obviousness Rationale
A PHOSITA would recognize that the PTD's AI-driven personalization of A1AT dosing represents a predictable extension of existing personalized medicine approaches, leveraging known machine learning techniques to optimize an established therapeutic method for GVHD mitigation. The combination of genomic profiling, real-time monitoring, and adaptive dosing represents an incremental technological improvement that would be obvious to a skilled practitioner seeking to enhance treatment precision.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,610 |
|---|---|
| Title | Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation |
| Assignee(s) | CSL Behring AG |